Metabolic Effects of Ritonavir-boosted Atazanavir and Darunavir in HIV-negative Adults: A Randomised Comparison

Frederick J Lee1*, Winnie WY Tong1, Robyn Richardson1, Nicola Mackenzie1 and Andrew Carr1,2

1Clinical Research Program, St. Vincent’s Centre for Applied Medical Research, Sydney, Australia
2HIV, Immunology and Infectious Diseases Unit, St. Vincent’s Hospital, Sydney, Australia

Abstract

Objectives: The increased cardiovascular risk historically associated with protease inhibitor (PI) use in HIV-infected individuals is only partly attributable to fasting dyslipidaemia, and may not apply to the currently recommended PI drugs - atazanavir and darunavir. In this prospective pilot study, we aimed to describe the isolated metabolic differences between atazanavir/ritonavir and darunavir/ritonavir on circulating fasting and post-prandial lipids (primary objective), and arterial stiffness, glycaemic and inflammatory markers (secondary objectives) by administering them as monotherapy to healthy, HIV-uninfected adults.

Methods: Participants were randomised 1:1 to receive open-label atazanavir (300 mg/day) or darunavir (800 mg/day), both boosted with ritonavir (100 mg/day), for 4 weeks. A standardised high-energy meal was consumed at weeks 0 and 4, with hourly post-prandial blood samples and arterial stiffness assessed for 4 hours. Mean fasting and post-prandial measurements were compared, the latter as the change in mean post-prandial incremental area under the curve.

Results: Twenty participants (10 atazanavir/ritonavir, 10 darunavir/ritonavir; 50% male, mean age 38 years, mean blood pressure 113/72 mmHg, mean total cholesterol 4.4 mmol/L, mean triglycerides 0.9 mmol/L) completed the study. After four weeks, fasting total cholesterol rose more with darunavir/ritonavir than atazanavir/ritonavir (+0.8 mmol/L vs. +0.3 mmol/L, respectively; p=0.041), as did low-density lipoprotein cholesterol (+0.1 mmol/L vs. +0.7 mmol/L, respectively; p=0.017). Between-group differences in post-prandial lipid changes were non-significant. Post-prandial decline in arterial stiffness was greater with atazanavir/ritonavir than darunavir/ritonavir (-27.6 h% vs. +0.1 h%, respectively; p=0.041). Bilirubin rose significantly with atazanavir/ritonavir but not darunavir/ritonavir (+29 µmol/L vs. +21 µmol/L, respectively; p=0.001). Changes in other parameters were similar.

Conclusion: Atazanavir/ritonavir has modestly, but significant, favourable metabolic and haemodynamic profiles over darunavir/ritonavir, evident even after short-term monotherapy. Post-prandial lipid effects were similar, however. Further study of treatment-emergent cardiovascular event incidence with darunavir/ritonavir therapy is required to determine the clinical relevance of this between-group difference.

Keywords: Protease inhibitors; Atazanavir; Darunavir; Ritonavir; Dyslipidaemia; Post-prandial lipids; Arterial stiffness; Tonometry; Bilirubin; Cardiovascular risk

Introduction

Protease inhibitor (PI)-based combination therapies for human immunodeficiency virus (HIV) infection possess potent anti-HIV activity, are widely available, and present the highest genetic barrier to resistance [1]. However, PIs are subject to a wide range of drug interactions, which may complicate dosing requirements and adherence. They have also been associated, in multiple studies, with fasting dyslipidaemia and/or an increase in overall cardiovascular risk [2]. This effect is independent of other known risk factors, including HIV infection itself.

The results of the D:A:D study indicate that only half of the cardiovascular risk specifically associated with PI-based combination therapy is attributable to fasting dyslipidaemia. Postulated additional, PI-induced effects include endothelial dysfunction [3], impaired cholesterol efflux from macrophages [4], and vascular wall effects leading to greater arterial stiffness [5]. Arterial stiffness relates measurement of change in arterial diameter and pressure at the same site, and is positively correlated with premature coronary artery disease, and is a validated, independent predictor of cardiovascular mortality in HIV-uninfected populations [6]. It is also associated with the metabolic syndrome, which is of emerging importance as non-acquired immune deficiency (AIDS) events become the dominant source of morbidity and mortality in the HIV-infected population [7].

Post-prandial (non-fasting) changes in circulating lipids, particularly triglycerides, have been prospectively associated with cardiovascular risk in the general population [8-10], but have not been widely assessed in the context of antiretroviral therapy. We have previously demonstrated that 4 weeks of low-dose ritonavir (100 mg/ day) in healthy, HIV-uninfected adults led to significant increases in post-prandial low-density lipoprotein (LDL) cholesterol, but not triglycerides, when compared to the HIV integrase strand transfer inhibitor raltegravir [11]. We have also demonstrated that mean arterial stiffness, as measured non-invasively via radial artery tonometry, is

*Corresponding author: Frederick J Lee, Clinical Research Program, St. Vincent’s Centre for Applied Medical Research, Sydney, Australia. Tel: +61 2 8382 3707; Fax: +61 2 8382 2090; E-mail: flee3@stvincents.com.au

Received December 31, 2013; Accepted February 20, 2014; Published February 28, 2014


Copyright: © 2014 Lee FJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
significantly higher in treatment-experienced than treatment-naïve HIV-infected individuals [12], corroborating the findings of an earlier study by Schillaci et al. [13].

The association with secondary dyslipidaemias and higher incidence of cardiovascular events has led to concerns about PI use in general, despite evidence that individual PI drugs do differ. In current United States Department of Health and Human Services antiretroviral guidelines, two PI drugs – atazanavir and darunavir (both boosted with ritonavir) – are listed as preferred options for initial therapy [14]. No association has been found between atazanavir and myocardial infarction or stroke [15]. Presently there is insufficient data to perform a similar analysis for darunavir. It would therefore be of interest to compare the metabolic and haemodynamic effects of darunavir and atazanavir; any relative differences may provide insights into mechanisms of cardiovascular risk.

While it is possible to estimate relative lipid effects of atazanavir and darunavir from separate clinical trials, such indirect comparisons are confounded by presence of active HIV infection – itself a cause of dyslipidaemia – and concomitant antiretroviral drugs [16-18]. This study simulates the isolated metabolic and vascular effects of ritonavir-boosted atazanavir and darunavir by administering them to healthy, HIV-uninfected adult volunteers.

Methods

This was a prospective open-label pilot study, conducted at a single centre in Sydney, Australia. Eligible volunteers were randomised 1:1 to receive ritonavir 100 mg/day with either atazanavir (300 mg/day) or darunavir (800 mg/day) for four weeks. All doses were to be taken with food. Randomisation was conducted according to a standard procedure, by an individual not involved in the study design or conduct.

All participants were healthy adult volunteers, capable of providing consent. They were eligible if they had a stable diet and weight, a body mass index of 20-30 kg/m², fasting triglycerides <2.0 mmol/L, and no contraindication to atazanavir, darunavir or ritonavir, or a known history of diabetes, or receiving anti-hypertensive or hypolipidaemic therapy, had not commenced cigarette smoking during the study. Mean adherence to study medication was similar in both groups (atazanavir/ritonavir 82% vs. darunavir/ritonavir 81%).

At weeks 0 and 4, participants consumed a standardised morning meal (1,386 calories: 38% fat, 16% protein, 45% carbohydrate), having fasted for 12 hours. They were required to abstain from any exercise or alcohol intake for the 48 hours prior. Fasting blood samples and arterial stiffness measurements were then taken hourly post-meal. Systemic arterial stiffness was examined as the augmentation index, defined as the difference between the second and first systolic peaks, as a percentage of the pulse pressure [22]. It was recorded via applanation tonometry at the radial artery, performed by an accredited operator. A validated proprietary transfer algorithm was then used to correct for heart rate (SphygmoCor® SCOR-PVx tonometer, AtCor Medical, Sydney, Australia), giving the final, adjusted, value for the augmentation index.

The primary objective was to describe relative changes in the circulating fasting and post-prandial lipid parameters – total, LDL and high-density lipoprotein (HDL) cholesterol fractions and triglycerides – after four weeks. Secondary outcomes of interest were the fasting and post-prandial measurements of arterial stiffness, glucose and inflammatory markers (C-reactive protein, D-dimer). All changes in post-prandial parameters were assessed as the mean incremental area under the curve, using previously described methods [11]. Between-group post-prandial comparisons were made by analysis of variance, fasting parameters were compared with the Mann-Whitney U-test, and p values were assigned a significance level of 0.05.

Safety was assessed by recording clinical adverse events (of any grade/severity) and serum biochemistry (hepatic transaminases, alkaline phosphatase, gamma glutamyl transferase, albumin, total protein and bilirubin). Adherence was determined by pill counting. All concomitant medications were recorded.

Results

Participant disposition and baseline characteristics

Twenty participants (male 50%, mean age 38 years, mean body mass index 24 kg/m², family history of hypercholesterolaemia 20%) completed the study (Figure 1). The mean age of the darunavir/ritonavir group was higher (44 years vs. 33 years, respectively). Other baseline characteristics are listed in Table 1. No participants commenced cigarette smoking during the study. Mean adherence to study medication was similar in both groups (atazanavir/ritonavir 82% vs. darunavir/ritonavir 81%).

Lipid parameters

Mean fasting baseline LDL cholesterol in both groups was 2.7 mmol/L. After four weeks, fasting cholesterol fractions rose in both groups (Table 2), with significant differences for total cholesterol (+0.3 mmol/L vs. +0.8 mmol/L, respectively; p=0.041) and LDL cholesterol (+0.1 mmol/L vs. +0.7 mmol/L, respectively; p=0.017). Mean changes in all post-prandial lipid fractions were similar between the groups (p>0.05).

Non- lipid parameters

A between-group difference was identified for arterial stiffness: with atazanavir/ritonavir, there was a significant fall in post-prandial arterial stiffness compared to darunavir, which remained unchanged (-27.6% vs. +0.1%, respectively; p=0.041). This difference was restricted to the post-prandial state, as the change in fasting arterial stiffness after four weeks was similar between the groups (+2.2% vs. +0.2%, respectively; p=0.670). Spearman’s correlation was used to describe the relationship between bilirubin rise at week four and the post-prandial change in arterial stiffness. Although a moderate, negative correlation
35 individuals screened for eligibility

23 randomly assigned to study groups

12 assigned to receive atazanavir/ritonavir (300/100 mg) once-daily

11 assigned to receive darunavir/ritonavir (800/100 mg) once-daily

1 did not start drug (withdrew consent)

1 discontinuation (rash)

10 completed study procedures

12 ineligible

9 entry criteria (5 elevated cholesterol, 3 high BMI, 1 high ALT)

2 withdrew consent before randomisation

1 investigator discretion (deemed unable to complete study procedures)

1 investigator discretion (deemed unable to complete study procedures)

Figure 1: Study profile and participant disposition.

BMI - Body mass index; ALT - alanine transaminase.

Table 1: Baseline characteristics and parameters of study participants.
In separate randomised studies of initial antiretroviral therapy, darunavir/ritonavir has had similar effects on fasting cholesterol fractions to lopinavir/ritonavir, which in turn had higher cholesterol levels than with atazanavir/ritonavir, both after 48 weeks of treatment in HIV-infected adults [23,24]. These findings are supported by a recent head-to-head comparison of atazanavir/ritonavir and darunavir/ritonavir [25]. However, these studies do not take into account the effect of HIV infection, nor of concomitant antiretroviral drugs. Our fas
ing lipid results are consistent with the above comparisons, but suggest it to be an independent effect of PI exposure, not confounded either by HIV viremia or by other antiretroviral drugs. Also, that this effect is evident after only four weeks suggests that PI-associated fasting dyslipidaemia occurs early in treatment. The modest, but significant difference in fasting LDL cholesterol also indicates that atazanavir/ritonavir may be less atherogenic than darunavir/ritonavir. This may be clinically relevant, as by study completion the mean LDL cholesterol level in participants receiving darunavir/ritonavir rose sufficiently from baseline to require consideration of hypolipidaemic therapy under the NCEP ATP III guidelines [20].

Based upon the fasting lipid results, it would have been reasonable to anticipate that atazanavir/ritonavir would also have a lesser effect upon the post-prandial lipid levels than darunavir/ritonavir. However, the two drugs were similar in their post-prandial lipid effects. Considered in light of recent D:A:D Study results indicating that atazanavir/ritonavir is not associated with an increased incidence of vascular events [15], it suggests that post-prandial lipid effects are unlikely to be a mechanism for vascular pathology with either atazanavir/ritonavir or darunavir/ritonavir.

Our finding that post-prandial arterial stiffness falls with atazanavir/ritonavir but not darunavir/ritonavir is a novel result. Haemodynamic parameters are highly sensitive to feeding states, and acute falls in arterial stiffness are a well-described physiological response to food intake [26,27]. In high cardiovascular risk conditions such as obesity and diabetes mellitus, this magnitude of this fall is attenuated. PI-based treatment of HIV infection has formerly been associated with higher indices of aortic stiffness when compared to an HIV-uninfected cohort [28], but our study is the first to compare and describe differences between specific PI drugs.

While cigarette smoking can accelerate arterial stiffness [29], the proportion of participants with a smoking history was similar between the two groups and no participants changed their smoking status throughout the study. This effect was also limited to the post-prandial state, and there were no outliers in the arterial tonometry data, making smoking unlikely to account for the between-group difference, and also making a regression to the mean effect unlikely.

The lower post-prandial arterial stiffness seen with atazanavir/ritonavir is also noteworthy given the 90% incidence of unconjugated hyperbilirubinaemia in that group. A link between hyperbilirubinaemia and cardiovascular risk has been explored in non-HIV conditions. Individuals with Gilbert’s syndrome, a common congenital cause of benign unconjugated hyperbilirubinaemia, have a prevalence of...
ischaemic heart disease up to six times lower than the general population. This effect is independently associated with hyperbilirubinaemia, and may be due to the potent anti-oxidant activity of bilirubin [30]. Lower mean arterial stiffness correlating with bilirubin levels has also been described in Gilbert’s syndrome [31], and atazanavir given to HIV-uninfected diabetics improved endothelial function [32]. The degree of hyperbilirubinaemia seen with atazanavir is similar to that in Gilbert’s syndrome [33], making it attractive as a biologically plausible candidate to at least partly explain the favourable cardiovascular profile of atazanavir/ritonavir. However, studies in HIV-infected cohorts have failed to identify a significant association between bilirubin, atazanavir and decreased vascular resistance [34-36]. Our study was not powered to examine this relationship, and no significant correlation was identified between bilirubin rise and post-prandial arterial stiffness. But it should be noted that these other studies used flow-mediated vasodilation as a marker of endothelial function, not applanation tonometry, and made no assessments relative to feeding state, which our study did.

The recruitment of healthy, HIV-uninfected volunteers meant that the effect of active HIV replication, itself a source of inflammation, was excluded as a confounding factor. Our study also used low-dose ritonavir as a pharmacokinetic booster – which reflects PI prescription in actual clinical use.

The principal limitations of our study were the small participant numbers and its short duration. It is possible that a longer treatment period with a larger cohort and a control group might have shown significant post-prandial lipid effects, or glycaemic and anthropometric changes consistent with nascent metabolic syndrome. It nevertheless provides a basis for further refinement of sample size and duration of follow-up for similar future studies. The small numbers also meant that despite randomisation, mean age of the darunavir/ritonavir group was 11 years higher than the atazanavir/ritonavir group. As arterial stiffness is known to increase with age, this may confound our between-group comparison of post-prandial arterial stiffness. It should also be noted that the augmentation index, although reproducible, is one of several methods of marking the systemic arterial stiffness non-invasively. It is a complex surrogate marker, influenced by multiple factors (height, blood pressure, heart rate, gender) that remain incompletely defined [6].

By our objective measurements atazanavir has favourable metabolic and vascular characteristics over darunavir, albeit modest in magnitude. A prospective examination of treatment-emergent cardiovascular events for darunavir/ritonavir, like the one completed for atazanavir/ritonavir [15], is required to see if this advantage translates to clinical relevance.

Acknowledgements

The authors thank the individuals who volunteered for this study, Kate-Louise Sinn and Alison Sevehon for co-ordinating post-prandial assessments, and Julie Hill for performing the statistical analysis of study data. Darunavir was supplied by Tibotec (Janssen-Cilag Australia). All authors contributed to study design and conduct. FJL composed the draft manuscript, with revisions provided by AC. All authors approved the final draft.

Disclosures

FJL receives a postgraduate research scholarship from the National Health and Medical Research Council of Australia (Grant Number 1017991); has received a Clinical Immunology Society Fellowship; and travel sponsorships from the Australasian Society of Clinical Immunology and Allergy, the Australasian Society for HIV Medicine and conference sponsorship from MSD and Gilead Sciences. WWY Tong, R Richardson, K Sinn and N Mackenzie declare no conflict of interest. AC has received research funding from amfAR, the Balnaves Foundation, Baxter, Gilead Sciences, MSD and Pfizer; consultancy fees from Gilead Sciences, GlaxoSmithKline/ViV Healthcare and MSD; lecture and travel sponsorships from Gilead Sciences, GlaxoSmithKline/ViV Healthcare, MSD and Serono; and has served on advisory boards for Gilead Sciences, GlaxoSmithKline/ViV Healthcare and MSD.

References


